GlaxoSmithKline has been awarded a four-year contract by the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority to support the ongoing development of GSK2251052 (GSK ‘052, formerly AN3665).
Discovered by Anacor, GSK ‘052 is a novel, boron-based systemic antibiotic being developed for the treatment of infections caused by Gram-negative bacteria.
Go deeper with GlobalData
The $94m grant will support the studies to evaluate the efficacy of GSK ‘052 against bioterrorism threats, Phase II clinical trials for ventilator-associated pneumonia and Phase III trials for complicated intra-abdominal infections.
Anacor CEO David Perry said that the financial support will help ensure the rapid development of the compound.
“With its novel mechanism of action, and potential to be administered both orally and intravenously, we believe GSK ‘052 has the potential to improve the lives of patients suffering from Gram-negative bacterial infections which have grown increasingly resistant to existing antibiotics,” Perry said.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
